Biotech

2023 - 3 - 22

'Banding together': 50 female biotech executives lay out plans for ... (Endpoints News)

Earlier this month, during the Silicon Valley Bank meltdown, Angie You recalled the speed with which female biotech CEOs were helping each other connect ...

This past weekend, 50 of about 125 women who are part of that Slack group and a broader coalition self-dubbed the Biotech Sisterhood met in person in Cancun for the second rendition of an annual summit connecting female biotech CEOs. The attendance list doubled that of the Earlier this month, during the

Post cover
Image courtesy of "CosmeticsDesign-Europe.com"

Blue biotech in beauty: 'We have a big task in terms of storytelling' (CosmeticsDesign-Europe.com)

Use of blue biotechnology in beauty continues to gain ground, but the concept remains complex for consumers and needs to be better defined before it reaches ...

“And every time I start to work with something I think is interesting for one reason, the day after, I discover more and more and more and more. And the humble mission we are on at Tiny Associates is trying to become the proof of concept with consumers that biotech is really exciting stuff and it’s a tool that can not only be applied for cosmetics but also for fashion, food (…) It’s really much larger than the cosmetics industry.” We have a job to do to make it accessible for everyone.” Scapagnini suggested that using the wine industry as a reference could be one smart way of simplifying it for consumers. The ocean is still lending a lot of secrets that will, in terms of perspective, really change the story of sustainability on this planet,” he said. All these properties remain in the shell,” Johansson said.

Post cover
Image courtesy of "Motley Fool"

Thinking of Buying Biotech Stocks? Do These 3 Things First (Motley Fool)

Therefore, the first thing to do if you're thinking of investing in a biotech stock is to ensure that your portfolio is diversified enough that you won't be ...

Therefore, the first thing to do if you're thinking of investing in a biotech stock is to ensure that your portfolio is diversified enough that you won't be breaking the bank by making a somewhat speculative investment in a biotech company. If you stick to those guidelines, a stumble in clinical trials that shaves 30% off your investment's share price won't leave a huge dent in your portfolio, which will also make it easier to think about whether mediocre clinical data warrants selling the stock. On the topic of biotechs blowing up, you really shouldn't be investing more than you can afford to lose when it comes to biotechs. Then, if your investment in Editas blows up because of sub-par clinical trial results, and it might, you won't need to kiss your whole portfolio goodbye -- just a small piece of it. Success rates tend to increase the closer a program gets to being submitted to regulators for consideration, and they also vary significantly depending on the target indication of the program in question. More mature biotechs, especially those that have medicines on the market, have a much greater ability to swing and miss and still have enough money left over to survive and even eventually thrive.

Post cover
Image courtesy of "Foley & Lardner LLP"

Building Biotech with Brains: Strategies for Maximizing Value of AI ... (Foley & Lardner LLP)

The rapid rise of artificial intelligence (AI) and machine learning (ML) in biotechnology products and services is becoming a driver of the personalized ...

For instance, a particular metric for a disease could be evaluated based on the presence of particular genetic markers or by the accumulation of misfolded proteins. Further, companies interested in drug discovery or novel therapeutics may utilize their ML or AI asset as an analytical tool for converting raw data into a useful metric for disease or a new drug candidate. While this may be true across the technical spectrum, the holistic viewpoint becomes particularly important on the frontier of new technologies involving both high-tech and biotechnology components.

Post cover
Image courtesy of "NNN"

The Intersection of AI and Biotech: Creating Valuable IP Assets (NNN)

The integration of artificial intelligence (AI) and machine learning (ML) in biotechnology products and services is becoming a driving force in the ...

Technology and legal teams can work together to develop stronger IP that applies machine learning applications to biotechnology, with a marketplace analysis that is aware of its unique IP pressure points. Whether a business is primarily focused on the AI components or the biotechnology components can inform its strategic direction for creating impactful patent assets. IP managers should consider all potential implementations of the integrated ML/biotech asset in order to cover the technical objectives underlying the commercial embodiments.

Explore the last week